MedTrace Logo

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

NCT01368887 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2011-06-08

No results posted yet for this study

Summary

The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.

Conditions

Interventions

DRUG

DPS-102

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

OTHER

Vehicle / Placebo

The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

DRUG

Calcipotriol Monotherapy

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

DRUG

Nicotinamide Monotherapy

The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Sponsors & Collaborators

  • DermiPsor, Ltd.

    lead INDUSTRY

Principal Investigators

  • Shay Marcus · Sponsor / DermiPsor Ltd.

  • Nelli Konnikov, M.D. · Veterans Administration (VA) Hospital - Brockton, MA

  • Nancy Naguib, M.D. · Brockton VA Hospital

  • Carolyn Stanger · Boston VA Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-11-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368887 on ClinicalTrials.gov